Becton, Dickinson & Stock

$196.63

1.29% yesterday

NYSE, Aug 21, 10:00 pm CET

ISIN

US0758871091

Symbol

BDX

Reports

Quarter | Annual

Index

NYSE Composite, S&P 500

Sector

Health Care Equipment & Services

Industry

Health Care Equipment & Supplies

Overview Dividends Analysts Charts News Strategies

Becton, Dickinson & Stock price

$196.63

-54.63 21.74% 5Y

NYSE, Closing price Thu, Aug 21 2025

-2.57 1.29%

ISIN

US0758871091

Symbol

BDX

Reports

Quarter | Annual

Index

NYSE Composite, S&P 500

Sector

Health Care Equipment & Services

Industry

Health Care Equipment & Supplies

Key metrics

Basic

Market capitalization

$57.1b

Enterprise Value

$75.7b

Net debt

$18.6b

Cash

$757.0m

Shares outstanding

286.6m

Valuation (TTM | estimate)

P/E

35.6 | 13.9

P/S

2.7 | 2.6

EV/Sales

3.5 | 3.4

EV/FCF

29.7

P/B

2.2

Dividends

DPS

$4.16

Yield 1Y | 5Y

2.1% | 1.5%

Growth 1Y | 5Y

9.5% | 6.2%

Payout 1Y | 3Y

64.9% | 65.3%

Increased

25 Years

Financials (TTM | estimate)

Revenue

$21.4b | $22.0b

EBITDA

$5.4b | $6.5b

EBIT

$3.0b | $5.4b

Net Income

$1.6b | $4.1b

Free Cash Flow

$2.6b

Growth (TTM | estimate)

Revenue

7.9% | 9.2%

EBITDA

4.0% | 24.3%

EBIT

2.5% | 84.1%

Net Income

13.7% | 140.8%

Free Cash Flow

-20.8%

Financial Health

Equity Ratio

45.2%

Return on Equity

6.6%

ROCE

6.5%

ROIC

Debt/Equity

0.8

EPS

$5.6

FCF per Share

$8.9

Short interest

1.9%

Employees

74k

Rev per Employee

$270.0k

As a Free StocksGuide user, you can view scores for all 7,014 stocks worldwide.

Get Started for Free Today

Becton, Dickinson & Stock Analysis

Unlock Scores for Free

??

21 Analysts have issued a Becton, Dickinson & forecast:

10x Buy

48%

11x Hold

52%

More details on Analyst Estimates Including Price Targets

21 Analysts have issued a Becton, Dickinson & forecast:

Buy

48%

Hold

52%

Analyst Estimates with Stock Price Targets

Financial data from Becton, Dickinson &

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Jun '25		+/- %
Revenue	21,386 21,386	8% 8% 100%
- Direct Costs	11,745 11,745	8% 8% 55%
Gross Profit	9,641 9,641	7% 7% 45%
- Selling and Administrative Expenses	5,167 5,167	9% 9% 24%
- Research and Development Expense	1,244 1,244	6% 6% 6%
EBITDA	5,440 5,440	4% 4% 25%
- Depreciation and Amortization	2,419 2,419	6% 6% 11%
EBIT (Operating Income) EBIT	3,021 3,021	3% 3% 14%
Net Profit	1,606 1,606	14% 14% 8%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Becton, Dickinson & Stock News

Positive

Seeking Alpha

●

4 days ago

Becton, Dickinson: Great Time To Buy This Dividend Aristocrat

BDX is now attractively valued with a forward PE of 13.7, well below its historical average, making it a compelling value stock. Strong growth in Pharmaceutical Systems and Interventional segments, margin expansion, and a robust innovation pipeline drive business momentum. The upcoming Waters Corp. spin-out will focus BDX on high-growth, recurring revenue segments, enhancing long-term earnings ...

Positive

Seeking Alpha

●

6 days ago

11 Dividend Aristocrats With Excellent Upside Potential In The Next Year

Dividend Growth Outperformance: For over 50 years, dividend growers have delivered market-beating returns with lower volatility. The BTI Example: British American Tobacco went from six years of stagnation to 63% gains in 2025, beating the Mag 7 and Bitcoin—underscoring the power of patience. I've found 11 dividend aristocrats with 70%+ quality scores and 50+% justified 12-month return potential...

Neutral

PRNewsWire

●

7 days ago

BD to Present at Wells Fargo 2025 Healthcare Conference

FRANKLIN LAKES, N.J. , Aug. 14, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the Wells Fargo 2025 Healthcare Conference on Wednesday, September 3, 2025 at 8:00 a.m.

More Becton, Dickinson & News

Company Profile

Becton, Dickinson & Co. is a medical technology company. The firm engages in the development, manufacture and sale of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. It operates through the following segments: BD Medical, BD Life Sciences and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect infectious diseases, healthcare-associated infections and cancers. The BD Interventional segment provides vascular, urology, oncology and surgical specialty products to hospitals, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via Homecare business. The company was founded in 1897 and is headquartered in Franklin Lakes, NJ.

Head office	United States
CEO	Thomas Polen
Employees	74,000
Founded	1897
Website	www.bd.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now